Supplementary Information

PyMT-1099, a versatile murine cell model for EMT in breast cancer

Meera Saxena*, Ravi Kiran Reddy Kalathur, Melanie Neutzner, and Gerhard Christofori*

Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland


*Corresponding authors:	Meera Saxena and Gerhard Christofori			
	Department of Biomedicine			
	University of Basel			
	Mattenstrasse 28			
	4058 Basel			
	Switzerland			
	E-mails:	gerhard.christofori@unibas.ch		
		meera.saxena@unibas.ch		

Co-authors' e-mail addresses:

Ravi Kiran Reddy Kalathur: ravikiranreddy.kalathur@unibas.ch Melanie Neutzner: melanie.neutzner@unibas.ch

Supplementary Figures

Figure S1



В

			PyMT-1099					NMuMG (E9)	
	ZO-1	Paxillin	Phalloidin	DAPI	Merge	ZO-1	Paxillin	Phalloidin	DAPI	Merge
UT							Contraction of the second			
1d									6. 6. 6. 6. 6. 6. 6. 6. 6.	
4d										
7d			RC .	0 • 9 • 0 9 • 0 2	B					R A
10d					< Contraction of the second se					

Figure S1 (relates to Figure 2). Time course of a TGFβ-induced EMT and MET in PyMT-1099 and in NMuMG cells.


PyMT-1099 and NMuMG (E9) cells were in parallel treated with TGF β for 0 (UT), 1, 4, 7 or 10 days. For MET, TGF β was withdrawn from 10 days treated cells, and monitored for EMT reversal at the indicated time-points.

(A) Photomicrographs represent the morphology of PyMT-1099 and NMuMG (E9) undergoing a TGF β -induced EMT. Magnification, 10 X.

(**B**) Immunofluorescence analysis was performed to assess the expression and/or localization of EMT markers ZO-1, focal adhesions (Paxillin) and actin stress fibers (Phalloidin); n=3. DAPI was used as a nuclear counterstain. Scale bar, 50 μm.

(C) Photomicrographs represent the morphology of PyMT-1099 and NMuMG (E9) undergoing MET upon TGF β withdrawal. Magnification, 10 X.

Figure S2








Figure S2 (relates to Figure 4). Histology and EMT marker expression in primary tumors of PyMT-1099 and PyMT-1099 LT cells.

(A) Untreated PyMT-1099 and PyMT-1099 LT cells were injected orthotopically into the mammary fat pads of NSG mice. H&E pictures represent the histology of primary tumors resected from NSG mice bearing tumors formed by PyMT-1099 or PyMT-1099 LT cells from the experiment described in Figure 4A. Representative pictures are shown from tumors of 4 out of the 6 mice used in the experiment.

(**B**) Immunofluorescence analysis was performed to assess the expression of the EMT markers FN1, VIM, E-CAD and N-CAD in tumors formed by PyMT-1099 or PyMT-1099 LT cells in NSG mice from the experiment described in Figure 4A. DAPI was used as a nuclear counterstain. Representative pictures are shown from tumors of 2 out of the 6 mice used in the experiment. Scale bar, 100µm.

(C) The graph represents the number of lung metastases formed in FVB/N mice injected with PyMT-1099 or PyMT-1099 LT cells through the tail vein; n=6. The mice were sacrificed 8 weeks post-injection and the lungs were resected for analysis of cancer cell colonization/ metastatic outgrowth.






Figure S3 (relates to Figure 5). Gene expression analysis of time courses of EMT and MET in PyMT-1099 cells.

(A) The heatmaps represent the correlation analysis of the biological duplicates of RNA samples from the TGF β EMT time course and the MET time course in PyMT-1099 cells that were subjected to RNA-Seq.

(B) Shown is the PCA analysis of the RNA samples from the TGF β EMT time course and the MET time course in PyMT-1099 cells.

(C) Volcano plots depict the differentially regulated genes at each time point of TGF β treatment of PyMT-1099 cells during EMT.

(D) Volcano plots depict the differentially regulated genes at each time point of PyMT-1099 cells during MET upon TGFβ withdrawal.

Figure S4




Figure S4. Source data- Uncropped scans from the genotyping PCR (agarose gel) presented in main Fig. 1




Figure S5. Source data- Uncropped scans from the immunoblotting results presented in main Fig. 2

Table S1

For genotyping						
	Forward (5'-3')	Reverse (5'-3')				
РуМТ	CGGCGGAGCGAGGAACTGAGG	TCAGAAGACTCGGCAGTCTTAG				
transgene						
For qPCRs						
Cdh1	CGACCCTGCCTCTGAATCC	TACACGCTGGGAAACATGAGC				
Cdh2	CAATGACGTCCACCCTGTTCT	CTGCCATGACTTTCTACGGAGA				
Fn1	CCCAGACTTATGGTGGCAATT	AATTTCCGCCTCGAGTCTGA				
Ncam	CAGGAGTCCTTGGAATTCAT	TGGAGAAGACGGTGTGTCTG				